

NACIQI: Unclear if Future of Accreditation Evolutionary vs. Revolutionary

3 December 2010

www.ubs.com/investmentresearch

■ We attended NACIQI this week; investment community was largely absent

Along with 100 industry stakeholders, we attended NACIQI Dec 1-2 in Washington DC. We were surprised by the absence of securities analysts in the audience, which indicates to us that investors potentially do not anticipate or perhaps understand the risk associated with changes to accreditation.

■ NACIQI to provide recommendation on HEA reauthorization next year

DOE Secretary Duncan has requested NACIQI to provide recommendations on the future of accreditation by this time next year. Next step: NACIQI will hold a policy forum in February (Exhibit 1). Based on conversations with members of NACIQI and accreditors in the audience, it is unclear to us whether such changes prove evolutionary or revolutionary. We posit that substantial changes to accreditation could meaningfully impact the operations of all postsecondary institutions, including those owned by companies that we cover.

■ HLC portion of hearing very tame – no negatives

HLC's accreditation remains intact, with NACIQI recommending that HLC's compliance report be accepted. NACIQI participants were quite congenial, far from the politicized confrontational affair that we were concerned it could be.

■ We continue to favour LOPE and APEI

Our favourite names from most to least favourite: LOPE; APEI; WPO; CPLA; APOL; STRA; DV; CECO, ESI, and COCO.

Ariel Sokol

Analyst
ariel.sokol@ubs.com
+1 212 713 8450

Denny Galindo

Associate Analyst
denny.galindo@ubs.com
+1 212 713 4471

Lack of Interest by Institutional Investors Startling

Investor fixation solely on gainful employment remains understandable but largely short-sighted in our opinion. We think that investors need to get up to speed on potential changes to accreditation and the potential impact that such changes could have on company business models. We remind investors that many dismissed negotiated rulemaking on program integrity at the beginning of the process, and could not comprehend that the government could meaningfully take action to reform the for-profit sector. We advise investors not to make a similar error as it relates to accreditation. We expect the February NACIQI policy forum to be better attended by the investment community.

Changes to Accreditation Could Prove Significant

Eduardo Ochoa, Assistant Education Secretary for Postsecondary Education, started off the NACIQI hearing by raising serious questions about accreditation and the federal role in it. Continually he suggested that “the stakes are higher” given increased federal funding to the sector, and questioned whether the accrediting agencies are up to the task of ensuring quality. Questions he posed included whether the right measures of student success exists. We acknowledge that such comments are not new – concerns regarding the current system of accreditation echo those raised in the Spellings Commission from 2006, particularly on the accountability and transparency of postsecondary institutions. However, what is new is that the process is currently underway to potentially change accreditation under an administration that has demonstrated a willingness and aptitude to put in motion meaningful change in the face of substantial opposition. Members of NACIQI and accreditors in the audience that we spoke with had little insight into how significant such changes could be.

We concede that at this time we do not know exactly what changes could take form, and what impact such changes could have on publicly traded postsecondary institutions. NACIQI has been charged to develop recommendations to the DOE for informing the 2013 reauthorization of the Higher Education Act (HEA). Assuming that the Act does pass in 2013, rules in place could take effect years afterward. Change in how postsecondary institutions provide quality and value to students is not imminent. However, we posit that material change could impact all of postsecondary, which at a bare minimum introduces elements of uncertainty that could continue to scare away institutional investors from the sector.

Some would suggest that the sector becomes investable again after some clarity exists regarding gainful employment rules and the impact on companies. Our understanding of the short seller thesis is that many for-profit institutions (or even non-profits) do not provide their students value. A change in the system of ensuring academic quality to quantifiable metrics, particularly for degree granting institutions (not so much for career schools that provide placement data) could in our opinion entice the shorts to stay for some time. In other words, investors potentially have to deal with changes to accreditation in addition to: the threat of increasing competition, price erosion if 90/10 were to

go away, increased customer acquisition costs, investigations by state attorney generals, and compliance with proposed gainful employment rules.

Exhibit 1: NACIQI February Policy Forum Worksheet

FEBRUARY POLICY FORUM

"Required Reading" (for before the Feb Forum)

- History of recognition and accreditation, and the linkage of recognition to student aid eligibility
- Current issues in accreditation

What is working (and not working) in the current system of recognition, accreditation, and student aid eligibility?

There is a huge (~\$150B) federal investment in education. How well does that investment serve us? How well does our current accreditation/recognition system protect the interests of the taxpayer who is underwriting that investment in education? If we were starting now, would we design *this* system? How might a system we would design *differ* from what currently exists?

Our current system draws on a variety of actors, definitions, and processes, which, in turn, poses a number of tensions, points of confusion, and areas of overlap.

- There are commonalities and divergences among notions of "*quality assurance*," "*continuous improvement*," and "*compliance*."
- There is tension between notions of gate-keeping for the availability of student aid, and notions of accreditation as a broader quality assurance and quality improvement process.
- There is confusion and incomplete overlap about compliance with regulation versus accreditation via peer review.
- There are a number of actors: federal, state, professional/trade/membership organizations, and the public—all of whom play varying roles and have varying interests.

Some of the questions that arise from the conjunction of the above, include:

- What should be the role of the federal government? Of the states? Of the trade/professional associations? Of students and families?
- What are the costs/benefits of a system in which accreditors serve as the gatekeepers to federal funds?
- What tensions arise from accreditors specifying a set of standards, and the Department requiring data that address a different set of criteria?
- To what extent does a peer review process serve the compliance/gatekeeping function (or vice versa)?
- Is it possible/desirable to distinguish between "quality assurance" determinations and "continuous improvement" recommendations? Between the minimum acceptable for gatekeeping functions, and the broader quality and/or quality-improvement determination functions.

These "crosscutting questions" also give rise to questions about the actors, definitions, and processes themselves:

RECOGNITION

- Of the current criteria for recognition, which have value/should continue, and which don't/should not continue?
- Might there be a "tiered" and/or "developmental" approach to recognition (perhaps both an "honors" designation (and interest in disseminating the best practices of these), and a non-accrediting status that designates agencies as not re-recognized but as in process for regaining accreditation authority)?

COMPLIANCE

- Should there be common standards for learning outcomes/student achievement (should the rule of construction stand, or should there be a set "standard" for student achievement?) Who should decide those? How should they be measured?

QUALITY ASSURANCE

- What should be the metrics of quality?
- What benefits (other than access to student aid) accrue in a quality assurance process? Are those benefits worth the costs?

AID ELIGIBILITY

- Can/should the link between student aid and accreditation be severed?
- Should there be separate metrics and/or forms of recognition for compliance with regulation for the purposes of quality determination versus aid eligibility (e.g., an "ROI" model for aid eligibility)?

ACTORS

- What should be the role of accreditation associations? Of the national, regional, specialized accreditors?
- What kind of transparency/public reporting is needed?
- What is the relationship between accreditation and state authorities?
- What implications do costs have for the relationship between the institution and the accreditor? For the accreditor and the recognition process?
- What is the value of accreditation/accreditation to its constituencies (consumers/clients/patrons)?
- To what extent does the current system work to the benefit of the consumer's (student's) decision making? Is it a useful source of information?

Last, there are questions about the process of considering possible changes:

- Are there other models (from other areas of regulated activity, other countries, other industries) that address these issues better?
- What would we gain/what would we lose by pursuing some of the proposed solutions?
- Would recommendations best be geared to changes that are systemic, comprehensive, and/or polishing?

OTHER TOPICS of interest (may also be raised in the context of the "what's working/not" list above)

POSSIBLE NEW/ALTERED ISSUES FOR HEA LAW or REG?

- *Transfer of accreditation/sale of an accredited institution*
- *Credit hours (how does one measure credit hours?)*
- *Length of recognition (Should the recognition period be shortened? (note that staff have concern about this one))*
- *Fiscal Integrity (what standards of fiscal integrity might apply?)*
- *Student mobility (how can institutions assist the movement of students across institutions?)*
- *Institutional productivity (should there be set acceptable completion/placement rates? Might the law/regs incentivize institutions to be more productive of college graduates/employed graduates? (note Carnegie Mellon and UMD initiatives))*
- *Geographic limitations on accreditors and expanding/constraining institutional choice or accreditor?*

ISSUES CONCERNING THE IMPLEMENTATION OF REGULATIONS

- *Concerns about need for verifiable data review for compliance with Secretary regs, relative to:*
 - concerns that imposing data requests that may be intrusive in terms of academic judgment and burdensome on accreditors*
 - concerns about a level of conformity and prescriptiveness that may not provide adequate flexibility for the diversity of institutions in US higher education*
 - concerns about the critical and sufficient data elements that are needed to evaluate the quality assurance process.*
- *Concerns about the stability of interpretation of review criteria, and about the opportunity for notice and comment on changes in interpretation*

Source: U.S. Department of Education

■ **Statement of Risk**

The main downside risks to postsecondary education stocks include: a deceleration in the growth rate or an actual decline in enrollments, driven by an improving economy and compliance with current and potentially new rules from regulatory bodies. An improving economy and increased competition could also increase sales and marketing costs which could in turn pressure margins. Given that federal student loans represent a majority of the company's revenue, legislation, whether enacted or proposed, could significantly alter company business models.

■ **Analyst Certification**

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request.

UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating	Rating Category	Coverage ¹	IB Services ²
Buy	Buy	51%	37%
Neutral	Hold/Neutral	40%	33%
Sell	Sell	9%	22%
UBS Short-Term Rating	Rating Category	Coverage ³	IB Services ⁴
Buy	Buy	less than 1%	20%
Sell	Sell	less than 1%	0%

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS. Rating allocations are as of 30 September 2010.

UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition
Buy	FSR is > 6% above the MRA.
Neutral	FSR is between -6% and 6% of the MRA.
Sell	FSR is > 6% below the MRA.
UBS Short-Term Rating	Definition
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.

KEY DEFINITIONS

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation.

Short-Term Ratings reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

Equity Price Targets have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES

UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Ariel Sokol; Denny Galindo.

Company Disclosures

Company Name	Reuters	12-mo rating	Short-term rating	Price	Price date
American Public Education Inc ¹⁶	APEI.O	Buy	N/A	US\$34.36	02 Dec 2010
Apollo Group Inc. ¹⁶	APOL.O	Neutral	N/A	US\$35.35	02 Dec 2010
Capella Education Co ¹⁶	CPLA.O	Neutral	N/A	US\$56.46	02 Dec 2010
Career Education Corp. ¹⁶	CECO.O	Neutral	N/A	US\$18.31	02 Dec 2010
Corinthian Colleges Inc. ^{13, 16}	COCO.O	Sell	N/A	US\$4.24	02 Dec 2010
Grand Canyon Education Inc ¹⁶	LOPE.O	Buy	N/A	US\$19.00	02 Dec 2010
Strayer Education Inc. ¹⁶	STRA.O	Neutral	N/A	US\$135.50	02 Dec 2010
Washington Post ¹⁶	WPO.N	Neutral	N/A	US\$387.61	02 Dec 2010

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

13. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company's common equity securities as of last month's end (or the prior month's end if this report is dated less than 10 days after the most recent month's end).
16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Publishing Administration.

Global Disclaimer

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is referred to as UBS SA.

This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein.

Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). UBS research complies with all the FSA requirements and laws concerning disclosures and these are indicated on the research where applicable. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this report, the report is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Prepared by UBS Menkul Değerler AS on behalf of and distributed by UBS Limited. **Russia:** Prepared and distributed by UBS Securities CJSC. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A.. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this report, the report is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** UBS South Africa (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South African Futures Exchange and the Bond Exchange of South Africa. UBS South Africa (Pty) Limited is an authorised Financial Services Provider. Details of its postal and physical address and a list of its directors are available on request or may be accessed at <http://www.ubs.co.za>. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate'), to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be provided upon request. **Hong Kong:** Distributed by UBS Securities Asia Limited. **Singapore:** Distributed by UBS Securities Pte. Ltd [mica (p) 039/11/2009 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte Ltd, an exempt financial advisor under the Singapore Financial Advisers Act (Cap. 110); or UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. The recipient of this report represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Ltd to institutional investors only. Where this report has been prepared by UBS Securities Japan Ltd, UBS Securities Japan Ltd is the author, publisher and distributor of the report. **Australia:** Distributed by UBS AG (Holder of Australian Financial Services License No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098) only to 'Wholesale' clients as defined by s761G of the Corporations Act 2001. **New Zealand:** Distributed by UBS New Zealand Ltd. An investment adviser and investment broker disclosure statement is available on request and free of charge by writing to PO Box 45, Auckland, NZ. **Dubai:** The research prepared and distributed by UBS AG Dubai Branch, is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (253825-x).

The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2010. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

